Neurocrine Biosciences, based in San Diego, develops pharmaceuticals for neurological disorders and employs 1,448 people. Its FDA-approved products include INGREZZA and Orilissa, with a strong clinical development pipeline.
David W Boyer sold 1,104 shares of NBIX on 31 January at $152.94 per share, worth a total of $169K. They now own 1,369 NBIX shares, or a 45% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
